FDA grants fast track status to Pyxis’ PYX-201

The FDA has granted fast track designation to Pyxis oncology’s PYX-201 for the treatment of adults with R/M HNSCC.

Feb 27, 2025 - 06:00

FDA grants fast track status to Pyxis’ PYX-201

The FDA has granted fast track designation to Pyxis oncology’s PYX-201 for the treatment of adults with R/M HNSCC.

Read the original article

Tags:

Previous Article

Student Enhances Century-Old Math Problem, Unlocking New Opportunities in Wind E...

Eli Lilly to expand US pharma manufacturing with four new sites

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

Risk adjusted net present value: What is the current va...

Dec 15, 2024

Sanofi’s frexalimab shows early potential in in Phase II multiple sclerosis trial

Sanofi’s frexalimab shows early potential in in Phase I...

Jun 1, 2023

Opinion: Contact sports cause CTE. So why are Americans watching more football than ever?

Opinion: Contact sports cause CTE. So why are Americans...

Feb 9, 2024